Clinical practice. Barrett's Esophagus.

[1]  R. Wong,et al.  Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. , 1999, Gastroenterology.

[2]  J. Ajani,et al.  Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. , 2000, The Journal of thoracic and cardiovascular surgery.

[3]  F. Ellis,et al.  Endoscopic surveillance of barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer , 1998, American Journal of Gastroenterology.

[4]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[5]  P. Siersema,et al.  Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. , 1999 .

[6]  S. Spechler.  The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. , 1999, Gastroenterology.

[7]  D. Castell,et al.  Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. , 1998, Gastroenterology.

[8]  V. Eckardt,et al.  Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. , 2001, The American journal of medicine.

[9]  B. Reid,et al.  Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus , 2000, Annals of Internal Medicine.

[10]  M. Omary,et al.  Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. , 1996, The Journal of clinical investigation.

[11]  R. Sandler,et al.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.

[12]  D. Castell,et al.  Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease , 1999, American Journal of Gastroenterology.

[13]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[14]  Katz,et al.  Gastro‐oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors , 1998, Alimentary pharmacology & therapeutics.

[15]  A. Sonnenberg,et al.  Medical decision analysis of endoscopic surveillance of Barrett’s oesophagus to prevent oesophageal adenocarcinoma , 2002, Alimentary pharmacology & therapeutics.

[16]  R. Sampliner,et al.  Short segment Barrett's esophagus—the need for standardization of the definition and of endoscopic criteria , 1998, American Journal of Gastroenterology.

[17]  R. Fitzgerald,et al.  Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. , 1999, Gastroenterology.

[18]  J K Greenson,et al.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. , 2001, Human pathology.

[19]  E. Kuipers,et al.  Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study , 1999, Gut.

[20]  Y. Guanrei,et al.  Natural history of early esophageal squamous carcinoma and early adenocarcinoma of the gastric cardia in the People's Republic of China. , 1988, Endoscopy.

[21]  Sushovan Guha,et al.  Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. , 2002, Gastroenterology.

[22]  R. Sampliner,et al.  Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.

[23]  E. Kuipers,et al.  Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. , 1997, Scandinavian journal of gastroenterology.

[24]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[25]  A. Bhattacharyya,et al.  Squamous Islands in Barrett's Esophagus: What Lies Underneath? , 1998, American Journal of Gastroenterology.

[26]  R. Goyal,et al.  Prevalence of metaplasia at the gastro-oesophageal junction , 1994, The Lancet.

[27]  A. Cameron,et al.  Epidemiology of columnar-lined esophagus and adenocarcinoma. , 1997, Gastroenterology clinics of North America.

[28]  A. Sonnenberg,et al.  Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. , 2001, Gastroenterology.

[29]  W. Chow,et al.  Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. , 2001, Gastroenterology.

[30]  Patricia L. Blount,et al.  An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.

[31]  R. Playford,et al.  Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study , 2000, BMJ : British Medical Journal.

[32]  M. Omary,et al.  Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. , 2000, Gastroenterology.

[33]  R. Hunt,et al.  Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. , 1997, Gastroenterology.

[34]  Dennis M. Riehle,et al.  Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. , 2001, Gastroenterology.

[35]  B. Overholt,et al.  Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. , 1999, Gastrointestinal endoscopy.

[36]  D. Castell,et al.  Gastroesophageal reflux disease in patients with columnar-lined esophagus. , 1997, Gastroenterology clinics of North America.

[37]  R. Hinder,et al.  Antireflux surgery. Indications, preoperative evaluation, and outcome. , 1999, Gastroenterology clinics of North America.

[38]  S. Spechler,et al.  Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. , 2002, Gastroenterology.

[39]  R. Sampliner,et al.  Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. , 2001, JAMA.

[40]  Prateek Sharma,et al.  Long-term follow-up of Barrett's high-grade dysplasia , 2000, American Journal of Gastroenterology.

[41]  J. Goldblum,et al.  The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression , 2000, American Journal of Gastroenterology.

[42]  H. Smart,et al.  Cost effectiveness of detecting Barrett's cancer. , 1996, Gut.